Distinct effects of rs895819 on risk of different cancers: an update meta-analysis
Metrics: PDF 1423 views | HTML 1971 views | ?
Muxiong Chen1,2,*, Wenpan Fang1,3,*, Xinkai Wu1, Suchen Bian1, Guangdi Chen1,3, Liqin Lu4 and Yu Weng5
1Institute of Environmental Health, Zhejiang University School of Medicine, Hangzhou, China
2Research Center of Molecular Medicine, Zhejiang University School of Medicine, Hangzhou, China
3Department of Public Health, Zhejiang University School of Medicine, Hangzhou, China
4Department of Oncology, Zhejiang Provincial People’s Hospital, Hangzhou, China
5Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
*These authors contributed equally to this work
Yu Weng, email: [email protected]
Liqin Lu, email: [email protected]
Guangdi Chen, email: [email protected]
Keywords: miR-27a, genetic variant, cancer risk, meta-analysis
Received: January 26, 2017 Accepted: April 12, 2017 Published: April 27, 2017
Previous studies have indicated an association between the genetic variant in pre-miR-27a rs895819 with A->G transition and cancer risk; however, the results remain inconsistent and somehow conflicting in different cancers. Therefore, to obtain a more reliable conclusion, we performed an update meta-analysis by searching PubMed database or other databases. Odds ratio (ORs) and 95% confidence interval (CIs) were calculated to evaluate cancer risk. A total of 34 case-control studies involving 15,388 cases and 18,704 controls were included. The results showed that rs895819 was associated with an increased cancer risk (GG vs. AA/AG: OR = 1.15, 95% CI = 1.02–1.29). Furthermore, stratification analyses revealed an association of rs895819 with increased cancer risk among Asians (GG vs. AA: OR = 1.17, 95% CI = 1.01–1.36; GG vs. AA/AG: OR = 1.18, 95% CI = 1.03–1.35), but not Caucasians. Interestingly, the [G] allele of rs895819 was significantly associated with decreased risk of breast cancer (G vs. A: OR = 0.91, 95% CI = 0.86–0.97). However, rs895819 was associated with increased risk of colorectal cancer (GG vs. AA: OR = 1.56, 95% CI = 1.31–1.85; GG vs. AA/AG: OR = 1.53, 95% CI = 1.30–1.79; G vs. A: OR = 1.19, 95% CI = 1.09–1.30) and lung cancer (GG vs. AA/AG: OR = 1.43, 95% CI = 1.00–2.04). In addition, no association was found between rs895819 and risk of gastric cancer or esophageal cancer. In conclusion, our findings suggest distinct effects of rs895819 on risk of different cancers, and future well-designed studies with large samples are required to further validate our results.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.